BR0114373A - Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante - Google Patents
Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinanteInfo
- Publication number
- BR0114373A BR0114373A BR0114373-5A BR0114373A BR0114373A BR 0114373 A BR0114373 A BR 0114373A BR 0114373 A BR0114373 A BR 0114373A BR 0114373 A BR0114373 A BR 0114373A
- Authority
- BR
- Brazil
- Prior art keywords
- fvii
- vitamin
- fviia
- host cell
- variants
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 229930003231 vitamin Natural products 0.000 title abstract 3
- 229940088594 vitamin Drugs 0.000 title abstract 3
- 235000013343 vitamin Nutrition 0.000 title abstract 3
- 239000011782 vitamin Substances 0.000 title abstract 3
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"CéLULA HOSPEDEIRA EUCARIóTICA, MéTODOS PARA A PRODUçãO DE FVII E DE FVIIA OU DE SUAS VARIANTES, DE UMA PROTEìNA DEPENDENTE DE VITAMINA K E DE UMA CéLULA HOSPEDEIRA EUCARIóTICA PRODUTORA DE FVII OU DE SEU ANáLOGO, VETOR RECOMBINANTE, FVII E FVIIa RECOMBINANTE OU SUAS VARIANTES, E, PROTEìNA DEPENDENTE DE VITAMINA K RECOMBINANTE". A presente invenção refere-se a um novo método para a preparação de proteínas dependentes de vitamina K. Em adição a presente invenção refere-se às novas células hospedeiras eucarióticas co-transfectadas e aos novos vetores recombinantes a serem usados neste método melhorado para a preparação de proteínas dependentes de vitamina K.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001456 | 2000-10-02 | ||
DKPA200100262 | 2001-02-16 | ||
DKPA200100430 | 2001-03-14 | ||
DKPA200100751 | 2001-05-14 | ||
PCT/DK2001/000635 WO2002029045A2 (en) | 2000-10-02 | 2001-10-02 | Method for the production of vitamin k-dependent proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114373A true BR0114373A (pt) | 2004-02-17 |
Family
ID=27439823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114373-5A BR0114373A (pt) | 2000-10-02 | 2001-10-02 | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
BR0114374-3A BR0114374A (pt) | 2000-10-02 | 2001-10-02 | Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114374-3A BR0114374A (pt) | 2000-10-02 | 2001-10-02 | Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação |
Country Status (18)
Country | Link |
---|---|
US (6) | US6903069B2 (pt) |
EP (6) | EP1325147A2 (pt) |
JP (4) | JP2004512835A (pt) |
KR (2) | KR100861470B1 (pt) |
CN (3) | CN1468303B (pt) |
AT (2) | ATE425254T1 (pt) |
AU (5) | AU2001291651A1 (pt) |
BR (2) | BR0114373A (pt) |
CA (2) | CA2422216C (pt) |
CZ (1) | CZ2003718A3 (pt) |
DE (2) | DE60137950D1 (pt) |
ES (2) | ES2344887T3 (pt) |
HU (2) | HUP0301245A3 (pt) |
IL (2) | IL154879A0 (pt) |
MX (1) | MXPA03002853A (pt) |
NO (1) | NO20031471L (pt) |
PL (2) | PL361058A1 (pt) |
WO (4) | WO2002029083A2 (pt) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6489447B1 (en) | 1998-05-06 | 2002-12-03 | Genentech, Inc. | Protein purification |
RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US20030040480A1 (en) * | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
PL368119A1 (en) | 2001-10-02 | 2005-03-21 | Novo Nordisk Health Care Ag | Method for production of recombinant proteins in eukaryote cells |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
HUP0402315A3 (en) * | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US7700733B2 (en) * | 2002-04-30 | 2010-04-20 | Bayer Healthcare Llc | Factor VII or VIIa polypeptide variants |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
CN1671410B (zh) | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的稳定化固体组合物 |
PT1517710E (pt) * | 2002-06-21 | 2011-07-08 | Novo Nordisk Healthcare Ag | Glicoformas do factor vii peguilado |
ATE505487T1 (de) * | 2002-09-30 | 2011-04-15 | Bayer Healthcare Llc | Fvii- oder fviia-varianten mit erhöhter koagulationswirkung |
EP3103869A1 (en) * | 2003-03-18 | 2016-12-14 | Novo Nordisk Health Care AG | Method for the production of factor vii polypeptides |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
ES2327044T3 (es) | 2003-03-20 | 2009-10-23 | Bayer Healthcare Llc | Variantes de fvii o fviia. |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
AU2004241698A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
NZ544728A (en) | 2003-06-19 | 2009-04-30 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
ES2382157T3 (es) * | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
US7687478B2 (en) * | 2003-06-30 | 2010-03-30 | Otsuka Chemical Co., Ltd. | Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
ES2335994T3 (es) * | 2003-07-01 | 2010-04-07 | Novo Nordisk Health Care Ag | Composicion farmaceutica liquida, acuosa de polipeptidos factor vii. |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
CA2534028A1 (en) * | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
ES2381110T3 (es) | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
JP2007506433A (ja) | 2003-09-23 | 2007-03-22 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ビタミンkエポキシド還元酵素遺伝子内の一塩基多型とワルファリン用量とを相関させるための方法および組成物 |
ES2565077T3 (es) | 2003-10-10 | 2016-03-31 | Novo Nordisk Health Care Ag | Método para producción en gran escala de un polipéptido en células eucariotas |
GB0324044D0 (en) | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
PT2189523E (pt) * | 2003-10-14 | 2012-01-24 | Baxter Healthcare Sa | Polipéptido de reciclagem de epóxido de vitamina k, vkorc1, um alvo terapêutico de cumarina e seus derivados |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1711513B1 (en) * | 2003-12-01 | 2014-07-02 | Novo Nordisk Health Care AG | Nanofiltration of factor vii solutions to remove virus |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP3378470A1 (en) * | 2003-12-19 | 2018-09-26 | Novo Nordisk Health Care AG | Stabilised compositions of factor vii polypeptides |
WO2005068620A1 (en) * | 2004-01-07 | 2005-07-28 | Novo Nordisk Health Care Ag | Method for the production of recombinant proteins |
DE602005019038D1 (de) | 2004-05-04 | 2010-03-11 | Novo Nordisk Healthcare Ag | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung |
BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
EP1797180A2 (en) * | 2004-09-29 | 2007-06-20 | Novo Nordisk Health Care AG | Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
EP1831363A1 (en) * | 2004-12-21 | 2007-09-12 | Novo Nordisk Health Care AG | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems |
PL1831242T3 (pl) * | 2004-12-23 | 2013-04-30 | Novo Nordisk Healthcare Ag | Zmniejszanie zawartości zanieczyszczeń białkowych w kompozycjach zawierających zależne od witaminy K białko będące przedmiotem zainteresowania |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
ATE541919T1 (de) * | 2005-02-11 | 2012-02-15 | Novo Nordisk Healthcare Ag | Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält |
MX349285B (es) | 2005-02-28 | 2017-07-20 | Baxalta Inc | Co-expresion recombinante de reductasa de epoxido de vitamina k subunidad 1 para mejorar la expresion de proteina dependiente de vitamina k. |
JP2008532544A (ja) | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンk依存性タンパク質を生産するための方法及び組成物 |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1874928A1 (en) * | 2005-04-13 | 2008-01-09 | AstraZeneca AB | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP2385125A3 (en) * | 2005-12-21 | 2012-04-11 | Inspiration Biopharmaceuticals, Inc. | Method of producing biologically active vitamin K dependent proteins by recombinant methods |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
DK2004214T3 (da) | 2006-03-16 | 2013-02-18 | Stellaris Pharmaceuticals Aps | Lokalbehandling med faktor VII |
KR101492422B1 (ko) * | 2006-04-11 | 2015-02-12 | 체에스엘 베링 게엠베하 | 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법 |
FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
EP2046372A2 (en) * | 2006-07-17 | 2009-04-15 | Novo Nordisk Health Care AG | Factor viia analogues with increased activity for treating thrombocytopenia |
US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
JP5167449B2 (ja) * | 2006-11-07 | 2013-03-21 | 独立行政法人科学技術振興機構 | 直鎖状核酸分子懸架支持体、直鎖状核酸分子伸長方法および直鎖状核酸分子標本 |
CN105838699A (zh) * | 2006-12-15 | 2016-08-10 | 巴克斯艾尔塔公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
JP5558106B2 (ja) * | 2007-01-03 | 2014-07-23 | ノボ ノルディスク ヘルス ケア アーゲー | 凝固第vii因子関連ポリペプチドの皮下投与 |
KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 g―csf를 이용하는 치료 방법 |
EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
AU2016238889B2 (en) * | 2007-04-26 | 2019-06-27 | Aptevo Biotherapeutics Llc | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
CA2683423C (en) * | 2007-04-26 | 2020-10-27 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
AU2014202989B2 (en) * | 2007-04-26 | 2016-07-07 | Aptevo Biotherapeutics Llc | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
EP2014299A1 (en) * | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
JP5784907B2 (ja) | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 組換え型vwf製剤 |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
CA2740919A1 (en) | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
CA2742107A1 (en) * | 2008-11-12 | 2010-05-20 | Baxter International Inc. | Method of producing serum-free insulin-free factor vii |
JP5027106B2 (ja) * | 2008-12-25 | 2012-09-19 | 一般財団法人阪大微生物病研究会 | 日本脳炎ウイルス抗原 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
JP5851410B2 (ja) | 2009-10-30 | 2016-02-03 | シーエヌジェイ ホールディングス、インク. | 組換えビタミンk依存性タンパク質の生成法 |
US20110136682A1 (en) * | 2009-12-04 | 2011-06-09 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
WO2012075138A1 (en) * | 2010-11-30 | 2012-06-07 | Progenetics Llc | Method of producing biologically active vitamin k dependent proteins in transgenic animals |
EP2655607A4 (en) | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS |
SG191298A1 (en) | 2010-12-22 | 2013-07-31 | Baxter Int | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
CN104717973A (zh) | 2012-10-10 | 2015-06-17 | 诺和诺德保健Ag(股份有限公司) | 因子vii多肽的液体药物组合物 |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
FR3006591B1 (fr) | 2013-06-11 | 2016-05-06 | Lab Francais Du Fractionnement | Composition de facteur vii presentant un point isoelectrique substantiellement homogene |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
NZ724826A (en) * | 2014-04-16 | 2022-07-29 | Cmc Biologics As | A high cell density fill and draw fermentation process |
ES2709994T3 (es) | 2014-06-04 | 2019-04-22 | Amgen Inc | Métodos de recolección en cultivos de células de mamífero |
US9714302B2 (en) | 2014-10-10 | 2017-07-25 | W. R. Grace & Co.—Conn. | Process for preparing spherical polymerization catalyst components for use in olefin polymerizations |
FR3034669B1 (fr) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
WO2017025566A1 (en) * | 2015-08-10 | 2017-02-16 | Glycotope Gmbh | Improved recombinant factor vii |
DK3383894T3 (da) * | 2015-12-02 | 2020-06-02 | CSL Behring Lengnau AG | Forbedrede medier til eksprimering af rekombinante vitamin k-afhængige proteiner |
EP3488858A1 (en) | 2017-11-27 | 2019-05-29 | Laboratoire Français du Fractionnement et des Biotechnologies | A von willebrand factor composition for use in treating a pathology mediated by angiogenesis |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189534A (en) * | 1976-11-11 | 1980-02-19 | Massachusetts Institute Of Technology | Cell culture microcarriers |
US4357422A (en) * | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
US4335215A (en) * | 1980-08-27 | 1982-06-15 | Monsanto Company | Method of growing anchorage-dependent cells |
US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4664912A (en) * | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
US4978616A (en) * | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
SE464816B (sv) * | 1985-10-15 | 1991-06-17 | Nilsson Kjell | Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning |
US4783940A (en) | 1985-12-28 | 1988-11-15 | Shimizu Construction Co., Ltd. | Concrete filled steel tube column and method of constructing same |
US5595886A (en) * | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
JPH01502080A (ja) * | 1986-11-17 | 1989-07-27 | ニュー・イングランド・メディカル・センター | 組み換えビタミンk依存性蛋白質のガンマカルボキシル化の増強 |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
JPH05508551A (ja) | 1990-07-23 | 1993-12-02 | ザイモジェネティクス,インコーポレイティド | ガンマーカルボキシラーゼおよび使用の方法 |
DK0574402T3 (da) * | 1990-11-26 | 1998-05-18 | Chiron Corp | Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf |
US5965789A (en) * | 1991-01-11 | 1999-10-12 | American Red Cross | Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals |
US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
JP3459416B2 (ja) | 1991-02-28 | 2003-10-20 | ザイモジェネティクス,インコーポレイティド | 修飾されたファクター▲vii▼ |
US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
IL104385A (en) * | 1992-01-17 | 1995-12-31 | Applied Research Systems | Method and device for growing biomass particles |
DK53792D0 (da) * | 1992-04-24 | 1992-04-24 | Novo Nordisk As | Fremgangsmaade til fremstilling af proteiner |
CA2111561A1 (en) * | 1992-05-01 | 1993-11-11 | Yoshiharu Takazawa | Fed batch culture method for protein secreting cells |
DE4221863C2 (de) | 1992-07-03 | 1997-04-17 | Stockhausen Chem Fab Gmbh | Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren |
US5510328A (en) * | 1994-04-28 | 1996-04-23 | La Jolla Cancer Research Foundation | Compositions that inhibit wound contraction and methods of using same |
WO1998004680A1 (en) * | 1996-07-26 | 1998-02-05 | University Of Manitoba | Serum-free medium for growth of anchorage-dependant mammalian cells |
EP0973544B1 (de) * | 1997-04-08 | 2001-06-27 | Baxter Aktiengesellschaft | Immuntolerante prothrombinkomplex-präparation |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
AU1262900A (en) * | 1998-11-06 | 2000-05-29 | Novo Nordisk A/S | Method for the production of fvii |
AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
EP1200561B1 (de) * | 1999-08-05 | 2006-06-14 | Baxter Aktiengesellschaft | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
UA74557C2 (en) * | 1999-09-03 | 2006-01-16 | Applied Research Systems | A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers |
AU2001270489B2 (en) * | 2000-04-26 | 2007-03-15 | Sanofi-Aventis Deutschland Gmbh | EDG8 receptor, its preparation and use |
-
2001
- 2001-10-02 DE DE60137950T patent/DE60137950D1/de not_active Expired - Lifetime
- 2001-10-02 EP EP01971735A patent/EP1325147A2/en not_active Withdrawn
- 2001-10-02 US US09/969,357 patent/US6903069B2/en not_active Expired - Lifetime
- 2001-10-02 BR BR0114373-5A patent/BR0114373A/pt not_active IP Right Cessation
- 2001-10-02 JP JP2002532653A patent/JP2004512835A/ja active Pending
- 2001-10-02 EP EP01971733A patent/EP1356074A2/en not_active Withdrawn
- 2001-10-02 WO PCT/DK2001/000632 patent/WO2002029083A2/en active Application Filing
- 2001-10-02 WO PCT/DK2001/000633 patent/WO2002029025A2/en active Application Filing
- 2001-10-02 HU HU0301245A patent/HUP0301245A3/hu unknown
- 2001-10-02 AU AU2001291651A patent/AU2001291651A1/en not_active Abandoned
- 2001-10-02 WO PCT/DK2001/000634 patent/WO2002029084A2/en active Application Filing
- 2001-10-02 PL PL01361058A patent/PL361058A1/xx not_active Application Discontinuation
- 2001-10-02 EP EP01971734A patent/EP1325113B1/en not_active Revoked
- 2001-10-02 AT AT01976037T patent/ATE425254T1/de not_active IP Right Cessation
- 2001-10-02 CZ CZ2003718A patent/CZ2003718A3/cs unknown
- 2001-10-02 CN CN018167462A patent/CN1468303B/zh not_active Expired - Fee Related
- 2001-10-02 WO PCT/DK2001/000635 patent/WO2002029045A2/en active Application Filing
- 2001-10-02 AU AU2001291652A patent/AU2001291652B2/en not_active Ceased
- 2001-10-02 CN CN201210226379.9A patent/CN102766668B/zh not_active Expired - Fee Related
- 2001-10-02 JP JP2002532615A patent/JP4361730B2/ja not_active Expired - Fee Related
- 2001-10-02 KR KR1020037004723A patent/KR100861470B1/ko not_active IP Right Cessation
- 2001-10-02 ES ES01971734T patent/ES2344887T3/es not_active Expired - Lifetime
- 2001-10-02 US US10/398,422 patent/US8202973B2/en not_active Expired - Fee Related
- 2001-10-02 JP JP2002532595A patent/JP4477299B2/ja not_active Expired - Fee Related
- 2001-10-02 CA CA2422216A patent/CA2422216C/en not_active Expired - Fee Related
- 2001-10-02 US US09/969,358 patent/US20020151471A1/en not_active Abandoned
- 2001-10-02 PL PL01361017A patent/PL361017A1/xx not_active Application Discontinuation
- 2001-10-02 HU HU0301267A patent/HUP0301267A3/hu unknown
- 2001-10-02 AU AU2001295431A patent/AU2001295431A1/en not_active Abandoned
- 2001-10-02 AT AT01971734T patent/ATE465253T1/de active
- 2001-10-02 BR BR0114374-3A patent/BR0114374A/pt not_active Application Discontinuation
- 2001-10-02 CA CA002422214A patent/CA2422214A1/en not_active Abandoned
- 2001-10-02 MX MXPA03002853A patent/MXPA03002853A/es not_active Application Discontinuation
- 2001-10-02 IL IL15487901A patent/IL154879A0/xx unknown
- 2001-10-02 KR KR1020037004725A patent/KR100880624B1/ko not_active IP Right Cessation
- 2001-10-02 ES ES01976037T patent/ES2323761T3/es not_active Expired - Lifetime
- 2001-10-02 EP EP01976037A patent/EP1325127B1/en not_active Expired - Lifetime
- 2001-10-02 EP EP10010149A patent/EP2311943A3/en not_active Withdrawn
- 2001-10-02 EP EP10003073A patent/EP2261330A1/en not_active Withdrawn
- 2001-10-02 AU AU9165201A patent/AU9165201A/xx active Pending
- 2001-10-02 DE DE60141908T patent/DE60141908D1/de not_active Expired - Lifetime
- 2001-10-02 JP JP2002532652A patent/JP2004510439A/ja active Pending
- 2001-10-02 CN CNA018166423A patent/CN1481438A/zh active Pending
- 2001-10-02 AU AU2001291653A patent/AU2001291653A1/en not_active Abandoned
- 2001-10-02 IL IL15488001A patent/IL154880A0/xx unknown
-
2003
- 2003-04-01 NO NO20031471A patent/NO20031471L/no not_active Application Discontinuation
- 2003-12-02 US US10/725,843 patent/US20050075289A1/en not_active Abandoned
-
2006
- 2006-12-21 US US11/643,607 patent/US20070122884A1/en not_active Abandoned
-
2009
- 2009-07-15 US US12/503,498 patent/US20090281022A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0114373A (pt) | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante | |
Hjelmeland et al. | Characteristics of two trypsin type isozymes isolated from the arctic fish capelin (Mallotus villosus). | |
McGuire et al. | Purification and characterization of a high molecular weight proteinase (macropain) from human erythrocytes | |
Deng et al. | Purification and characterization of a novel fibrinolytic enzyme from the polychaete, Neanthes japonica (Iznka) | |
BR0214653A (pt) | Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleìco, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, cepa, uso de pelo menos uma protease, método para melhorar o valor nutricional de uma ração animal, aditivo para ração animal, composição de ração animal, e, método para o tratamento de proteìnas vegetais | |
ATE500323T1 (de) | Subtilisin-variante | |
Wu et al. | Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells | |
Moura-da-Silva et al. | Evidence for heterogeneous forms of the snake venom metalloproteinase jararhagin: a factor contributing to snake venom variability | |
KR102500777B1 (ko) | 우유-응고 특성이 개선된 키모신 변이체 | |
MXPA06001173A (es) | Metodo analitico para la pancreatina y composiciones comparables. | |
Nakamura et al. | Contribution of calpain Lp82–induced proteolysis to experimental cataractogenesis in mice | |
US8513386B2 (en) | FVIII-independent FIX-mutant proteins for hemophilia a treatment | |
Tan et al. | Purification and properties of the L-amino acid oxidase from monocellate cobra (Naja naja kaouthia) venom. | |
EP1129179A4 (en) | UDP-galactose: BETA-I (N) -acetyl-glucosamine BETA1,3 galactosyltransferases, BETA3Gal-T5 | |
DK1209985T3 (da) | Modification af proteiners skumningsegenskaber | |
Baek et al. | Molecular cloning of a novel ubiquitin-specific protease, UBP41, with isopeptidase activity in chick skeletal muscle | |
Griffon et al. | Thermodynamics of Na+ binding to coagulation serine proteases | |
ATE307205T1 (de) | Gefrorenes lebensmittel | |
Seetharam et al. | Cloning and expression of rat coagulation factor VII | |
Tomkinson et al. | Structure-function studies of recombinant murine tripeptidyl-peptidase II: the extra domain which is subject to alternative splicing is involved in complex formation | |
Vatandoost et al. | The effects of influencing factors on γ-carboxylation and expression of recombinant vitamin K dependent coagulation factors | |
Wang et al. | Correlation between the glycan variations and defibrinogenating activities of acutobin and its recombinant glycoforms | |
Sugihara et al. | Comparative study of three proteinases from the venom of the Chinese habu snake (Trimeresurus mucrosquamatus). | |
Torres et al. | Bmoo FIBMP-I: a new fibrinogenolytic metalloproteinase from Bothrops moojeni snake venom | |
Kim et al. | Processing and subcellular localization of ADAM2 in the Macaca fascicularis testis and sperm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NOVO NORDISK HEALTH CARE AG (CH) Free format text: TRANSFERIDO DE: NOVO NORDISK A/S |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |